Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus

被引:186
作者
Bultink, IEM
Lems, WF
Kostense, PJ
Dijkmans, BAC
Voskuyl, AE
机构
[1] Vrije Univ Amsterdam, Ctr Med, Slotervaart Hosp, NL-1081 HV Amsterdam, Netherlands
[2] Jan Breemen Inst, NL-1081 HV Amsterdam, Netherlands
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 07期
关键词
D O I
10.1002/art.21110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To examine the prevalence of and risk factors for low bone mineral density (BMD) and vertebral fractures in patients with systemic lupus erythematosus (SLE). Methods. We studied 107 SLE patients. Demographic and clinical data were collected, and radiographs of the thoracic and lumbar spine and BMD measurements by dual x-ray absorptiometry were performed. Vertebral deformities were scored according to the method of Genant et al: fractures were defined as a reduction of >= 20% of the vertebral body height. Osteoporosis was defined as a T score less than -2.5 SD and osteopenia as a T score less than -1.0 SD in at least I region of measurement. Results. Osteopenia was present in 39% of the patients and osteoporosis in 4% (93% female; mean age 41.1 years). In multiple regression analysis, low BMD in the spine was associated with a low body mass index (BMI), postmenopausal status, and 25-hydroxyvitamin D deficiency. Low BMD in the hip was associated with low BMI and postmenopausal status. At least 1 vertebral fracture was detected in 20% of the patients. Vertebral fractures were associated with ever use of intravenous methylprednisolone and male sex. Conclusion. Risk factors for low BMD in SLE patients are low BMI, postmenopausal status, and vitamin D deficiency. While osteoporosis defined as a low T score was found in only 4% of the patients, osteoporotic vertebral fractures were detected in 20%. The high prevalence of low BMD and vertebral fractures implies that more attention must be paid to the prevention and treatment of osteoporosis and fractures in SLE.
引用
收藏
页码:2044 / 2050
页数:7
相关论文
共 40 条
[1]   Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage [J].
Becker, A ;
Fischer, R ;
Scherbaum, WA ;
Schneider, M .
LUPUS, 2001, 10 (11) :809-814
[2]   Bone mineral density in women with systemic lupus erythematosus [J].
Bhattoa, HP ;
Bettembuk, P ;
Balogh, A ;
Szegedi, G ;
Kiss, E .
CLINICAL RHEUMATOLOGY, 2002, 21 (02) :135-141
[3]   Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus [J].
Bhattoa, HP ;
Kiss, E ;
Bettembuk, P ;
Balogh, A .
RHEUMATOLOGY INTERNATIONAL, 2001, 21 (03) :97-102
[4]   Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures [J].
Black, DM ;
Arden, NK ;
Palermo, L ;
Pearson, J ;
Cummings, SR .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (05) :821-828
[5]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[6]   Bone mineral density changes in women with systemic lupus erythematosus [J].
Boyanov, M ;
Robeva, R ;
Popivanov, P .
CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) :318-323
[7]   INCIDENCE OF CLINICALLY DIAGNOSED VERTEBRAL FRACTURES - A POPULATION-BASED STUDY IN ROCHESTER, MINNESOTA, 1985-1989 [J].
COOPER, C ;
ATKINSON, EJ ;
OFALLON, WM ;
MELTON, LJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 (02) :221-227
[8]   ASSESSMENT OF THE EFFECT OF ORAL CORTICOSTEROIDS ON BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PRELIMINARY-STUDY WITH DUAL ENERGY X-RAY ABSORPTIOMETRY [J].
DHILLON, VB ;
DAVIES, MC ;
HALL, ML ;
ROUND, JM ;
ELL, PJ ;
JACOBS, HS ;
SNAITH, ML ;
ISENBERG, DA .
ANNALS OF THE RHEUMATIC DISEASES, 1990, 49 (08) :624-626
[9]   LOSS OF BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FORMIGA, F ;
MOGA, I ;
NOLLA, JM ;
PAC, M ;
MITJAVILA, F ;
ROIGESCOFET, D .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (04) :274-276
[10]  
Formiga F, 1997, CLIN EXP RHEUMATOL, V15, P387